

Exhibit D



**It is time
to examine
the facts.**

IAB Therapy still remains the first-line choice

The facts:

- IAB therapy, with low complication rate, should be considered in early stages of cardiogenic shock.¹
- No clear signal of superior outcome was observed with patients with Impella® CP support when compared with the IABP.²
- Bleeding complications in the IMPRESS™ trial were significantly higher in the Impella arm than the IABP arm (33% vs. 8%).²
- Initiation of therapy prior to primary PCI vs. after PCI decreased mortality in cardiogenic shock from 53% to 25%.²

1. Atkinson TM, Ohman EM, O'Neill WW, et al. JACC Cardiovasc Interv. 2016 May 9;9(9):871-83.

2. Ouweneel DM, Eriksen E, Sjaun KD, et al. J Am Coll Cardiol. 2016 Oct 27.



**Take a closer look: View a presentation
on practical patient support by Dr. Jay Thomas**
www.cathlabdigest.com/patientsupport

GETINGE 